MedTrace Logo

Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine

NCT04411836 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 960

Last updated 2024-10-08

No results posted yet for this study

Summary

Health care facility based, randomized, controlled, open label, superiority trial with 3 arms

Conditions

  • Vivax Malaria
  • Plasmodium Vivax
  • Malaria, Vivax
  • Malaria Relapse

Interventions

DRUG

Tafenoquine

patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ).

DRUG

Primaquine

patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)

Sponsors & Collaborators

  • University of Melbourne

    collaborator OTHER

  • National Centre for Parasitology, Entomology and Malaria Control, Cambodia

    collaborator OTHER

  • Mahidol Oxford Tropical Medicine Research Unit

    collaborator OTHER

  • Ethiopian Public Health Institute

    collaborator OTHER_GOV

  • Universitas Sumatera Utara

    collaborator OTHER

  • Arba Minch University

    collaborator OTHER

  • Aga Khan University

    collaborator OTHER

  • Menzies School of Health Research

    lead OTHER

Principal Investigators

  • Kamala Thriemer, MD, MPH, PhD · Menzies School of Health Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-25
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • Cambodia
  • Ethiopia
  • Indonesia
  • Pakistan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04411836 on ClinicalTrials.gov